



FIG E1. Analysis subsamples for examining associations between exposure to parabens and current asthma among all children and with ED visits and asthma attacks among children aged 6 to 19 years with asthma (NHANES 2005-2014).

TABLE E1. Associations of exposure to parabens with respiratory morbidity measures among children with asthma and with current asthma prevalence, adjusting for serum cotinine concentrations*

| | Subsample of children with cotinine data (cotinine not in the model), cPOR | | | Subsample of children with cotinine data (cotinine not in the model), aPOR | | | Subsample of children with cotinine data and cotinine in the model, aPOR | | | Stratified results by sex on the subsample of children with cotinine data and cotinine in the models | | | | | | |
|----------------|--|-----------|------|--|-----------|---------|--|-----------|------|--|-----------|---------|-----------------|------------------|------------------|-------|
| | cPOR | P value | aPOR | P value | aPOR | P value | aPOR | P value | aPOR | P value | aPOR | P value | aPOR | P value | P _{int} | |
| Morbidity | | | | | | | | | | | | | Boys (n = 166) | Girls (n = 146) | | |
| ED visits | | | | | | | | | | | | | | | | |
| (n = 312) | | | | | | | | | | | | | | | | |
| BP | 1.18 | 0.61-2.31 | .61 | 1.26 | 0.58-2.73 | .56 | 1.25 | 0.58-2.72 | .57 | 1.97 | 0.59-6.55 | .26 | 0.90 | 0.35-2.36 | .83 | .32 |
| EP | 1.05 | 0.50-2.22 | .89 | 1.10 | 0.49-2.49 | .81 | 1.12 | 0.50-2.52 | .78 | 1.08 | 0.40-2.96 | .88 | 1.15 | 0.35-3.75 | .82 | .94 |
| MP | 1.01 | 0.54-1.89 | .97 | 1.03 | 0.47-2.26 | .93 | 1.03 | 0.47-2.26 | .94 | 2.86 | 1.31-6.25 | .01† | 0.50 | 0.18-1.39 | .18 | .003† |
| PP | 1.00 | 0.64-1.57 | 1.00 | 1.05 | 0.53-2.08 | .90 | 1.04 | 0.52-2.07 | .91 | 2.37 | 1.17-4.79 | .02† | 0.56 | 0.23-1.40 | .21 | .003† |
| Asthma attacks | | | | | | | | | | | | | | | | |
| (n = 312) | | | | | | | | | | | | | | | | |
| BP | 1.77 | 0.91-3.47 | .09 | 2.63 | 1.31-5.28 | .01† | 2.64 | 1.32-5.31 | .01† | 2.43 | 1.02-5.78 | .04 | 2.81 | 1.03-7.70 | .05 | .83 |
| EP | 0.80 | 0.43-1.50 | .49 | 1.13 | 0.58-2.20 | .71 | 1.13 | 0.58-2.20 | .72 | 0.65 | 0.27-1.57 | .34 | 1.82 | 0.65-5.09 | .25 | .15 |
| MP | 0.69 | 0.45-1.06 | .09 | 0.80 | 0.51-1.28 | .35 | 0.81 | 0.51-1.28 | .36 | 0.81 | 0.47-1.40 | .44 | 0.80 | 0.44-1.46 | .47 | .99 |
| PP | 0.79 | 0.54-1.17 | .23 | 1.00 | 0.63-1.59 | 1.00 | 1.00 | 0.63-1.59 | .99 | 1.14 | 0.69-1.88 | .61 | 0.91 | 0.50-1.65 | .75 | .46 |
| Prevalence | | | | | | | | | | | | | Boys (n = 1465) | Girls (n = 1368) | | |
| Current asthma | | | | | | | | | | | | | | | | |
| (n = 2833) | | | | | | | | | | | | | | | | |
| BP | 0.83 | 0.59-1.18 | .30 | 0.83 | 0.58-1.20 | .32 | 0.83 | 0.58-1.19 | .31 | 1.07 | 0.65-1.76 | .80 | 0.69 | 0.40-1.17 | .16 | .25 |
| EP | 1.15 | 0.85-1.56 | .37 | 1.10 | 0.81-1.50 | .54 | 1.11 | 0.81-1.51 | .52 | 1.09 | 0.66-1.78 | .73 | 1.12 | 0.71-1.77 | .61 | .93 |
| MP | 1.17 | 0.93-1.46 | .17 | 1.21 | 0.92-1.59 | .17 | 1.21 | 0.92-1.60 | .17 | 1.41 | 1.04-1.92 | .03 | 1.03 | 0.70-1.52 | .87 | .16 |
| PP | 1.15 | 0.96-1.37 | .13 | 1.17 | 0.95-1.43 | .13 | 1.17 | 0.95-1.44 | .13 | 1.24 | 0.96-1.59 | .10 | 1.11 | 0.83-1.50 | .47 | .58 |

BP and EP values are modeled as less than LOD versus LOD or greater, and MP and PP values are modeled as log₁₀ concentrations in nanograms per milliliter.cPOR, Crude prevalence odds ratio; P_{int}, interaction term P value (sex*biomarker concentration term).*Crude models were adjusted for log₁₀ creatinine concentrations and multivariable models were adjusted for age in years, sex (except stratified models), poverty income ratio (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), survey cycle year (2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014), log₁₀ creatinine concentrations, and serum cotinine concentrations.

†P < .05.

TABLE E2. Associations of exposure to parabens with respiratory morbidity measures among children with asthma and with current asthma, prevalence, adjusting for BMI z scores*

| | Subsample of children with BMI data (BMI z score not in the model), cPOR | | | Subsample of children with BMI data (BMI z score not in the model), aPOR | | | Subsample of children with BMI data and BMI z score in the model, aPOR | | | Stratified results by sex on the subsample of children with BMI data and BMI z score in the models | | | | | | |
|------------------------------|--|-----------|-------|--|-----------|-------|--|-----------|-------|--|-----------|-------|-----------------|------------------|-------|------------------|
| | P | | | P | | | P | | | P | | | P | | | P _{int} |
| | cPOR | 95% CI | value | aPOR | 95% CI | value | aPOR | 95% CI | value | aPOR | 95% CI | value | aPOR | 95% CI | value | |
| Morbidity | | | | | | | | | | | | | Boys (n = 247) | Girls (n = 199) | | |
| ED visits (n = 446) | | | | | | | | | | | | | Boys (n = 247) | Girls (n = 199) | | |
| BP | 1.43 | 0.78-2.61 | .25 | 1.44 | 0.73-2.83 | .29 | 1.46 | 0.75-2.85 | .26 | 2.19 | 0.78-6.12 | .14 | 1.04 | 0.45-2.37 | .93 | .27 |
| EP | 1.07 | 0.56-2.05 | .84 | 1.07 | 0.52-2.23 | .85 | 1.10 | 0.52-2.33 | .79 | 1.16 | 0.48-2.80 | .74 | 1.06 | 0.36-3.13 | .91 | .90 |
| MP | 1.22 | 0.70-2.13 | .48 | 1.22 | 0.63-2.38 | .55 | 1.24 | 0.65-2.36 | .52 | 2.59 | 1.41-4.75 | .003† | 0.59 | 0.24-1.45 | .25 | .001† |
| PP | 1.09 | 0.72-1.66 | .67 | 1.15 | 0.64-2.07 | .64 | 1.16 | 0.65-2.05 | .62 | 2.16 | 1.22-3.81 | .008† | 0.62 | 0.28-1.37 | .23 | .002† |
| Asthma attacks (n = 446) | | | | | | | | | | | | | Boys (n = 247) | Girls (n = 199) | | |
| BP | 1.51 | 0.85-2.67 | .16 | 1.78 | 0.93-3.41 | .08 | 1.74 | 0.92-3.27 | .09 | 1.52 | 0.74-3.10 | .25 | 1.94 | 0.76-4.98 | .17 | .67 |
| EP | 0.69 | 0.41-1.17 | .17 | 0.82 | 0.46-1.43 | .47 | 0.80 | 0.45-1.41 | .43 | 0.54 | 0.27-1.09 | .09 | 1.15 | 0.46-2.87 | .76 | .21 |
| MP | 0.76 | 0.55-1.06 | .10 | 0.82 | 0.56-1.19 | .28 | 0.81 | 0.55-1.18 | .27 | 0.87 | 0.57-1.34 | .53 | 0.75 | 0.43-1.30 | .30 | .62 |
| PP | 0.77 | 0.55-1.06 | .11 | 0.86 | 0.59-1.25 | .42 | 0.85 | 0.59-1.24 | .41 | 0.95 | 0.65-1.40 | .80 | 0.77 | 0.45-1.31 | .33 | .43 |
| Prevalence | | | | | | | | | | | | | Boys (n = 2056) | Girls (n = 1937) | | |
| Current asthma (n = 3993) | | | | | | | | | | | | | Boys (n = 2056) | Girls (n = 1937) | | |
| BP | 0.83 | 0.63-1.08 | .16 | 0.83 | 0.62-1.11 | .20 | 0.84 | 0.63-1.11 | .22 | 0.95 | 0.64-1.41 | .80 | 0.75 | 0.48-1.19 | .22 | .48 |
| EP | 1.15 | 0.90-1.48 | .26 | 1.10 | 0.85-1.42 | .46 | 1.11 | 0.86-1.43 | .40 | 1.08 | 0.74-1.58 | .69 | 1.14 | 0.78-1.67 | .48 | .84 |
| MP | 1.21 | 1.01-1.45 | .04† | 1.18 | 0.95-1.47 | .14 | 1.20 | 0.96-1.48 | .10 | 1.36 | 1.05-1.77 | .02† | 1.03 | 0.75-1.41 | .87 | .16 |
| PP | 1.21 | 1.04-1.41 | .01† | 1.20 | 1.01-1.44 | .04† | 1.22 | 1.02-1.45 | .03† | 1.25 | 1.00-1.56 | .05 | 1.18 | 0.91-1.53 | .21 | .72 |

BP and EP values are modeled as less than LOD versus LOD or greater, and MP and PP values are modeled as log₁₀ concentrations in nanograms per milliliter.cPOR, Crude prevalence odds ratio; P_{int}, interaction term P value (sex*biomarker concentration term).*Crude models were adjusted for log₁₀ creatinine concentrations, and multivariable models were adjusted for age in years, sex (except stratified models), poverty income ratio (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), survey cycle year (2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014), log₁₀ creatinine concentration, and BMI z score.

†P < .05.

TABLE E3. Associations of exposure to parabens with respiratory morbidity measures among children with asthma and with current asthma prevalence, adjusting for log₁₀ triclosan, bisphenol A, and 2,5-dichlorophenol concentrations*

| | All children (adjusting for log ₁₀ triclosan, bisphenol A, and 2,5-dichlorophenol concentrations), cPOR | | | | | | Stratified results by sex adjusting for log ₁₀ concentrations of triclosan, bisphenol A, and 2,5-dichlorophenol | | | | | |
|------------------------------|--|-----------|---------|------|-----------|---------|--|-----------|---------|-----------------|-----------|---------|
| | All children, cPOR | | | aPOR | | | Boys (n = 248) | | | Girls (n = 202) | | |
| | cPOR | 95% CI | P value | aPOR | 95% CI | P value | aPOR | 95% CI | P value | aPOR | 95% CI | P value |
| Morbidity | | | | | | | | | | | | |
| ED visits (n = 450) | | | | | | | | | | | | |
| BP | 1.43 | 0.78-2.63 | .24 | 1.36 | 0.67-2.79 | .39 | 2.22 | 0.78-6.28 | .13 | 0.88 | 0.36-2.12 | .77 |
| EP | 1.07 | 0.56-2.05 | .84 | 1.06 | 0.52-2.13 | .87 | 1.18 | 0.48-2.88 | .72 | 0.96 | 0.35-2.62 | .94 |
| MP | 1.22 | 0.70-2.14 | .48 | 1.24 | 0.65-2.37 | .51 | 2.70 | 1.42-5.14 | .003† | 0.57 | 0.25-1.30 | .18 |
| PP | 1.10 | 0.72-1.66 | .66 | 1.18 | 0.67-2.10 | .56 | 2.24 | 1.25-4.02 | .01† | 0.60 | 0.30-1.24 | .17 |
| Asthma attacks (n = 450) | | | | | | | | | | | | |
| BP | 1.52 | 0.86-2.68 | .15 | 1.81 | 0.93-3.55 | .08 | 1.56 | 0.76-3.19 | .22 | 2.06 | 0.76-5.58 | .15 |
| EP | 0.69 | 0.41-1.16 | .16 | 0.82 | 0.47-1.43 | .49 | 0.55 | 0.27-1.11 | .09 | 1.22 | 0.50-2.98 | .65 |
| MP | 0.76 | 0.55-1.05 | .09 | 0.81 | 0.56-1.18 | .27 | 0.85 | 0.56-1.29 | .44 | 0.78 | 0.45-1.33 | .35 |
| PP | 0.77 | 0.56-1.06 | .11 | 0.86 | 0.59-1.26 | .44 | 0.94 | 0.64-1.38 | .74 | 0.80 | 0.47-1.36 | .40 |
| Prevalence | | | | | | | | | | | | |
| Current asthma (n = 4023) | | | | | | | | | | | | |
| BP | 0.82 | 0.63-1.08 | .15 | 0.81 | 0.61-1.08 | .15 | 0.96 | 0.64-1.42 | .82 | 0.71 | 0.45-1.12 | .14 |
| EP | 1.14 | 0.89-1.47 | .29 | 1.07 | 0.83-1.38 | .61 | 1.08 | 0.74-1.58 | .69 | 1.06 | 0.72-1.56 | .77 |
| MP | 1.21 | 1.01-1.45 | .04† | 1.16 | 0.93-1.44 | .19 | 1.34 | 1.03-1.74 | .03† | 0.98 | 0.71-1.35 | .90 |
| PP | 1.21 | 1.04-1.41 | .02† | 1.18 | 0.99-1.41 | .07 | 1.24 | 0.99-1.55 | .06 | 1.13 | 0.87-1.47 | .37 |

BP and EP values are modeled as less than LOD versus LOD or greater, and MP and PP values are modeled as log₁₀ concentrations in nanograms per milliliter. CPOR, Crude prevalence odds ratio; P_{int}, interaction term P value (sex*biomarker concentration term).

*Crude models were adjusted for log₁₀ creatinine concentrations, and multivariable models were adjusted for age in years, sex (except stratified models), poverty income ratio (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), survey cycle year (2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014), and log₁₀-transformed creatinine, triclosan, bisphenol A, and 2,5-dichlorophenol concentrations.

†P < .05.